Drug Profile
Research programme: neurodegenerative disease therapies - Cambria Pharmaceuticals
Alternative Names: CMB-03350; CMB-44282; CMB-50213; CMB-50381; CMB-53042Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cambria Biosciences LLC
- Developer Cambria Pharmaceuticals; Northwestern University
- Class Small molecules
- Mechanism of Action Superoxide dismutase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Cerebral ischaemia
- Discontinued Brain injuries; Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
- 16 Jul 2016 No recent reports of development identified for research development in Cerebral-ischaemia in USA
- 07 Nov 2007 Pharmacodynamics data from an in vitro study in Amyotrophic lateral sclerosis presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)